FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options to over 300 mutations, benefiting 300 newly eligible U.S. patients. Suzetrigine for acute pain aligns with NOPAIN Act ...
Sales are expected to surpass that total in 2024. Like Vertex’s top-selling drug Trikafta, Alyftrek is a three-drug combination that uses a compound called tezacaftor as its chemical backbone. The two ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback